UGT1A1 and acute kidney injury: Therefore, the innovation of ASFEE lies in its ability to integrate “detoxification by upregulating UGT1A1”, “cell protection by inhibiting PI3K/Akt”, and “anti-inflammatory/anti-apoptotic” effects, proposing a new multi-level and synergistic treatment strategy for cisplatin-induced acute kidney injury.